Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | ARTV | Common Stock | Conversion of derivative security | +145K | 145K | Jul 22, 2024 | Direct | F1 | |||
transaction | ARTV | Common Stock | Other | $500K | +49K | +33.79% | $10.20* | 194K | Jul 22, 2024 | Direct | F2 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | ARTV | Series B Preferred Stock | Conversion of derivative security | -145K | -100% | 0 | Jul 22, 2024 | Common Stock | 145K | Direct | F1 |
Wellington Biomedical Innovation Master Investors (Cayman) I L.P. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.
Id | Content |
---|---|
F1 | Each share of Series B Preferred Stock converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the "IPO"), the Series B Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Series B Preferred Stock had no expiration date. |
F2 | Represents the conversion of outstanding simple agreement for future equity in the amount of $500,000.00 into shares of the Issuer's common stock upon closing of the Issuer's IPO at a 15% discount to the IPO price. |